


Liver Tumor Program



KIMBERLY J. DAVIES, MD
Co-director, Oncologist



MAUREEN M. JONAS, MD
Co-director, Hepatologist



HEUNG BAE KIM, MD
Co-director, Liver Transplant and Hepatobiliary Surgeon

The Liver Tumor Program at Dana-Farber/Children's Hospital Cancer Center provides a multi-disciplinary, individualized approach to the management of children with malignant and benign tumors of the liver. Our integrated service accepts patient referrals for treatment, second opinions and consultations regarding the potential need for liver transplantation. As a program within Dana-Farber Cancer Institute, a Children's Oncology Group (COG) institution, we provide care for patients with hepatoblastoma and other hepatic neoplasms who are enrolled in COG therapeutic trials. Our team includes expert radiologists and pathologists. We accept referrals for radiologic second opinions to determine resectability of tumors and to advise on the need for liver transplantation. The Liver Transplant Program has transplanted 16 patients with hepatoblastoma or hepatocellular carcinoma over the last ten years with excellent success.

Scheduling

Call our New Patient Coordinator toll free at **1-888-Pedi-Onc (733-4662)**. The coordinator will request the following materials:

- pathology slides from initial diagnosis to current date with written reports
- imaging studies with reports (CD-ROM or DICOM-compatible preferred; hard copy films also accepted)
- one- to two-page medical summary letter including patient's diagnosis, treatment to date, and questions from provider and/or patient

Materials may be sent to:

Dana-Farber Cancer Institute

c/o Jill Ilie
450 Brookline Avenue
Boston, MA 02215
Phone: 617-632-5508 | Fax: 617-582-7434
Email: jill_ilie@dfci.harvard.edu

International

For families residing outside of the United States, please contact Children's International Health Services, which facilitates the medical review of patient records and appointment scheduling and provides assistance with customs and immigration, transportation, hotel and housing accommodations.

01-617-355-5209 | childrenshospital.org/international
international.center@childrens.harvard.edu

Highlights

We are the only pediatric Liver Tumor Program in New England with a Liver Transplant Program and the ability to integrate oncology, radiology, and pathology expertise, allowing us to offer cutting-edge, comprehensive care to children with resectable or unresectable hepatic malignancies.

Areas of expertise

Our collaborative team evaluates and treats a wide range of conditions, including:

- biliary rhabdomyosarcoma
- embryonal sarcoma of the liver
- hepatoblastoma
- hepatocellular carcinoma
- mesenchymal hamartomas
- vascular tumors of the liver (e.g. hemangioma, Kaposiform hemangioendothelioma, etc.)
- other rare tumors of the liver

Outcomes

- Number of transplants completed for liver malignancy: 16 (1 living donor, 9 whole organ, 6 split)
- One-year patient/graft survival: 94%
- Three-year patient/graft survival: 88%

Liver Tumor Program

Research

We are committed to moving the field of liver transplantation for pediatric hepatic malignancies forward. Our liver transplant team has focused on the feasibility of minimizing post-transplant immunosuppression in patients who have been pre-treated with chemotherapy. Through our participation in the Children's Oncology Group hepatoblastoma therapeutic trials, rare tumor biology studies, and the international registry for Pediatric Liver Transplantation for hepatic malignancies (PLUTO), we contribute to knowledge about pediatric hepatic malignancies and the indications for liver transplantation in the management of these diseases.

Selected publications

Suh MY, Wang K, Gutweiler JR, Misra MV, Krawczuk LE, Jenkins RL, Lillehei CW, Jonas MM, Kim HB. Safety of minimal immunosuppression in liver transplantation for hepatoblastoma. *J Pediatr Surg*. 2008 Jun;43(6):1148-52.

Wang LL, Filippi RZ, Zurakowski D, Archibald T, Vargas SO, Voss SD, Shamberger RC, Davies K, Kozakewich H, Perez-Atayde AR. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. *Am J Surg Pathol*. 2010 Mar;34(3):287-99.

Our team

Our team includes members from all disciplines at Dana-Farber/Children's Hospital Cancer Center and the Liver Transplant Program of Children's Hospital Boston. The Liver Tumor Program is led by:

Kimberly J. Davies, MD, Oncology

kimberly_davies@dfci.harvard.edu

Maureen M. Jonas, MD, Hepatology

maureen.jonas@childrens.harvard.edu

Heung Bae Kim, MD, Surgery

heung.kim@childrens.harvard.edu

To make a referral, call our New Patient Coordinator toll free at 877-695-1611.